BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

OncoImmunology

Volumn 2, Issue 10, 2013, Pages

  Cooper, Zachary A ^a   Frederick, Dennie T ^b   Juneja, Vikram R ^c,d   Sullivan, Ryan J ^b,c   Lawrence, Donald P ^b,c   Piris, Adriano ^b,c   Sharpe, Arlene H ^c   Fisher, David E ^b,c   Flaherty, Keith T ^b,c   Wargo, Jennifer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

BRAF; Melanoma; T cells; TILs; Vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CDR3 GENE; CLONAL VARIATION; CONTROLLED STUDY; DRUG RESPONSE; DRUG TARGETING; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; METASTATIC MELANOMA; T RECEPTOR BETA CHAIN CODING GENE; TREATMENT DURATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

EID: 84890268839     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26615     Document Type: Article

References (32)

1. Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol 2010; 22:178-83; PMID:20401974; http://dx.doi. org/10.1097/CCO.0b013e32833888ee
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949- 54; PMID:12068308; http://dx.doi.org/10.1038/ nature00766
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507- 16; PMID:21639808; http://dx.doi.org/10.1056/ NEJMoa1103782
4. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707- 14; PMID:22356324; http://dx.doi.org/10.1056/ NEJMoa1112302
5. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. Combined BRAF; MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-703; PMID:23020132; http://dx.doi.org/10.1056/NEJMoa1210093
6. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213-9; PMID:20551059; http://dx.doi. org/10.1158/0008-5472.CAN-10-0118
7. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-31; PMID:23307859; http://dx.doi. org/10.1158/1078-0432.CCR-12-1630
8. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012; 18:5329-40; PMID:22850568; http://dx.doi. org/10.1158/1078-0432.CCR-12-1632
9. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013; 19:393-403; PMID:23204132; http://dx.doi.org/10.1158/1078- 0432.CCR-12-1626
10. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386-94; PMID:22156613; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479
11. Robins HS, Srivastava SK, Campregher PV, Turtle CJ, Andriesen J, Riddell SR, Carlson CS, Warren EH. Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med 2010; 2:47ra64; PMID:20811043; http://dx.doi.org/10.1126/ scitranslmed.3001442
12. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487:500- 4; PMID:22763439; http://dx.doi.org/10.1038/ nature11183
13. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968-72; PMID:21107320; http://dx.doi.org/10.1038/nature09627
14. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387-90; PMID:22113612; http:// dx.doi.org/10.1038/nature10662
15. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011; 364:772- 4; PMID:21345109; http://dx.doi.org/10.1056/ NEJMcibr1013704
16. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18:683- 95; PMID:21156289; http://dx.doi.org/10.1016/j. ccr.2010.11.023
17. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494:251-5; PMID:23302800; http://dx.doi.org/10.1038/nature11814
18. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci USA 2013; 110:5957-62; PMID:23533272; http:// dx.doi.org/10.1073/pnas.1219232110
19. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008; 68:4853-61; PMID:18559533; http://dx.doi.org/10.1158/0008- 5472.CAN-07-6787
20. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009; 106:20411-6; PMID:19915144; http://dx.doi.org/10.1073/pnas.0905833106
21. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973-7; PMID:21107323; http://dx.doi. org/10.1038/nature09626
22. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013; 3:338-49; PMID:23171796; http://dx.doi. org/10.1158/2159-8290.CD-12-0313
23. Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013; 3:350-62; PMID:23288408; http://dx.doi.org/10.1158/2159- 8290.CD-12-0470
24. Katayama CD, Eidelman FJ, Duncan A, Hooshmand F, Hedrick SM. Predicted complementarity determining regions of the T cell antigen receptor determine antigen specificity. EMBO J 1995; 14:927-38; PMID:7534228
25. Goyarts EC, Vegh Z, Kalergis AM, Hörig H, Papadopoulos NJ, Young AC, Thomson CT, Chang HC, Joyce S, Nathenson SG. Point mutations in the beta chain CDR3 can alter the T cell receptor recognition pattern on an MHC class I/peptide complex over a broad interface area. Mol Immunol 1998; 35:593-607; PMID:9823758; http://dx.doi. org/10.1016/S0161-5890(98)00056-X
26. Yazdi AS, Morstedt K, Puchta U, Ghoreschi K, Flaig MJ, Rocken M, Sander CA. Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J Invest Dermatol 2006; 126:393-8; PMID:16374454; http://dx.doi.org/10.1038/sj.jid.5700082
27. Buchholz VR, Flossdorf M, Hensel I, Kretschmer L, Weissbrich B, Gräf P, Verschoor A, Schiemann M, Höfer T, Busch DH. Disparate individual fates compose robust CD8+ T cell immunity. Science 2013; 340:630-5; PMID:23493420; http://dx.doi. org/10.1126/science.1235454
28. Shindo T, Kim TK, Benjamin CL, Wieder ED, Levy RB, Komanduri KV. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood 2013; 121:4617-26; PMID:23575444; http://dx.doi. org/10.1182/blood-2012-12-476218
29. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http:// dx.doi.org/10.1056/NEJMoa1200694
30. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
31. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/ NEJMoa1003466
32. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228- 47; PMID:19097774; http://dx.doi.org/10.1016/j. ejca.2008.10.026